Journals / art / 2020 / Cilt: 35 - Sayı: 1

Screening for Fabry Disease in Patients With Juvenile Systemic Lupus Erythematosus

Journal
art
Pages
7–12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: We do not suggest routine screening of FD in patients with juvenile SLE; however, prospective studies with larger sample sizes are needed for further analysis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to determine the prevalence of Fabry disease (FD) among patients with juvenile systemic lupus erythematosus (SLE).
📊
Key Findings & Data:Patients and methods: This cross-sectional study included 76 juvenile SLE patients (12 males; 64 females; mean age 16±3.3 years; range, 8 to 23.5 years) who were diagnosed according to 1997 update of the 1982 American College of Rheumatology revised criteria for classification of SLE.
💡
Conclusion & Impact:Conclusion: We do not suggest routine screening of FD in patients with juvenile SLE; however, prospective studies with larger sample sizes are needed for further analysis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: This study aims to determine the prevalence of Fabry disease (FD) among patients with juvenile systemic lupus erythematosus (SLE). Patients and methods: This cross-sectional study included 76 juvenile SLE patients (12 males; 64 females; mean age 16±3.3 years; range, 8 to 23.5 years) who were diagnosed according to 1997 update of the 1982 American College of Rheumatology revised criteria for classification of SLE. Since the majority of patients were female, alpha-galactosidase A gene was investigated for mutations resulting in FD. Lysosomal accumulation of globotriaosylsphingosine (lyso-Gb3) was further evaluated in mutation positive subjects by using dried blood spot testing. Results: Alpha-galactosidase A gene screening did not yield any positive mutation in our 74 subjects. However, a heterozygous p.D313Y mutation was found in two females. These subjects were further investigated for lyso-Gb3 levels in dried blood spot samples and the levels of lyso-Gb3 being normal lead to exclusion of FD in these two patients. Conclusion: We do not suggest routine screening of FD in patients with juvenile SLE; however, prospective studies with larger sample sizes are needed for further analysis.

🔖

Cite This Article

KIYKIM, E., ŞAHİN, S., ZUBARIOĞLU, T., BARUT, K., ADROVIC, A., CANSEVER, M. Ş., ZEYBEK, A. Ç. A., KASAPÇOPUR, Ö. (2020). Screening for Fabry Disease in Patients With Juvenile Systemic Lupus Erythematosus. art, Cilt: 35 - Sayı: 1, 7–12. https://ajindex.com/articles/210392

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Desnick RJ, Ioannou YA, Eng CM, a-GalactosidaseA deficiency: Anderson-Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw Hill; 2001. p. 3733-74
  2. Nandagudi A, Jury EC, Alonzi D, Butters TD, Hughes S, Isenberg DA. Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry’s disease. Lupus 2013;22:1070-6
  3. Navratil M, Ivkovic Jurekovic I. Chloroquine toxicity misdiagnosed as Fabry disease associated with systemic lupus erythematosus and hashimoto thyroiditis. J Rheumatol 2017;44:1940
  4. Rahman P, Gladman DD, Wither J, Silver MD. Coexistence of Fabry’s disease and systemic lupus erythematosus. Clin Exp Rheumatol 1998;16:475-8
  5. Majima K, Ishizaki T, Inoue T, Hori Y, Egami J, Oohara A, et al. A case of Fabry’s disease associated with lupus nephritis. Nihon Jinzo Gakkai Shi 1992;34:1189-94. [Abstract] 6. Rosenmann E, Kobrin I, Cohen T. Kidney involvement in systemic lupus erythematosus and Fabry’s disease. Nephro 1983;34:180-4
  6. Martinez P, Aggio M, Rozenfeld P. High incidence of autoantibodies in Fabry disease patients. J Inherit Metab Dis 2007;30:365-9
  7. Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 2017;76:1965-73
  8. Sahin S, Adrovic A, Barut K, Canpolat N, Ozluk Y, Kilicaslan I, et al. Juvenile systemic lupus erythematosus in Turkey: demographic, clinical and laboratory features with disease activity and outcome. Lupus 2018;27:514-9
  9. Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 2008;152:550-6
  10. Couture J, Silverman ED. Update on the pathogenesis and treatment of childhood-onset systemic lupus erythematosus. Curr Opin Rheumatol 2016;28:488-96
  11. Artim-Esen B, ahin S, Çene E, ahinkaya Y, Barut K, Adrovic A, et al. Comparison of disease characteristics, organ damage, and survival in patients with juvenile-onset and adult-onset systemic lupus erythematosus in a combined cohort from 2 tertiary centers in Turkey. J Rheumatol 2017;44:619-25
  12. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the